October 13 2011

Cancer Research Technology – the commercial arm of Cancer Research UK – today (Thursday) announced the appointment of Peter Chambré as its new chairman.

Peter is currently chairman of two private equity-backed pharmaceutical businesses, Xellia Pharmaceuticals and 7TM Pharma and he is a non-executive director of BTG plc and Spectris plc. From 2002 until 2006, Peter was Chief Executive of Cambridge Antibody Technology Group plc.

He succeeds Melanie Lee who has been chairman of CRT since 2003.

Michael Pragnell, chairman of Cancer Research UK, said: “We’re delighted to welcome Peter Chambré who will be bringing extremely valuable industry experience to the Board, as CRT is seeking to create new partnerships between industry and academia.

“I’d like to thank Melanie Lee for her exceptional contribution to CRT and as a former Trustee of Cancer Research UK. We wish her all the best for the future.”

See more articles

Notes to Editors

CRT’s Board of Directors
Michael Pragnell, Chairman of Cancer Research UK
Dr Andy Richards
Dr J. Barrie Ward
Keith Blundy, Chief Executive Officer, CRT
Clive Stanway, CRT’s Chief Scientific Officer
Phil L'Huillier, CRT’s Director of Business Management
Hamish Ryder, CRT’s Director of Drug Discovery
Harpal Kumar, Cancer Research UK’s Chief Executive and former CEO of Cancer Research Technology

About Cancer Research Technology

Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com

CRT's discovery laboratories build on exploratory research to create attractive commercial opportunities through collaboration with research institutes worldwide. Therapeutic programmes are then out-licensed for further development following identification of a suitable partner.

About Cancer Research UK

• Cancer Research UK is the world's leading charity dedicated to saving lives through research
• The charity's groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
• Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last thirty years.
• Cancer Research UK supports research into all aspects of cancer through the work of more than 4,800 scientists, doctors and nurses.
• Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
• For further information about Cancer Research UK's work or to find out how to support the charity,
  please call 020 7121 6699
  or visit www.cancerresearchuk.org.uk.